IP Library › Granted Patent US 8,313,943
Granted Patent B2
US 8,313,943 · App. 12/564,283 · Granted Nov 20, 2012

Genetically modified human natural killer cell lines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,313,943
App. No.
12/564,283
Granted
Nov 20, 2012
Kind
B2
Abstract

The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Claims (2)

1. A modified NK-92 cell available from American Type Culture Collection as Deposit No. PTA-8836.

2. A modified NK-92 cell available from American Type Culture Collection as Deposit No. PTA-6967.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2020
From: THE FOX CHASE CANCER CENTER FOUNDATION
To: THE INSTITUTE FOR CANCER RESEARCH
Reel/Frame 053562/0938 →
CONFIRMATORY LICENSE Recorded Jan 8, 2014
From: FOX CHASE CANCER CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031936/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2009
From: CAMPBELL, KERRY S
To: FOX CHASE CANCER CENTER
Reel/Frame 023386/0925 →